

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


Single Technology Appraisal

Remibrutinib for treating chronic spontaneous urticaria inadequately controlled by H1-antihistamines ID6356


Final Stakeholder List

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
Company	General
Novartis Pharmaceuticals	All Wales Therapeutics and Toxicology
(remibrutinib)	Centre
(**************************************	Allied Health Professionals Federation
Patient/carer groups	Board of Community Health Councils in
Allergy UK	Wales
South Asian Health Foundation	British National Formulary
Specialised Healthcare Alliance	Care Quality Commission
	Department of Health - Northern Ireland
Healthcare professional groups	Healthcare Improvement Scotland
British Association of Dermatologists	Medicines and Healthcare products
British Dermatological Nursing Group	Regulatory Agency
British Geriatrics Society	National Association of Primary Care
British Skin Foundation	National Pharmacy Association
British Society for Allergy & Clinical	NHS Confederation
Immunology	NHS Wales Joint Commissioning Group
British Society for Cutaneous Allergy	Scottish Medicines Consortium
British Society for Immunology	Welsh Government
Primary Care Dermatology Society	VVOIGH GOVORNINGING
Royal College of General Practitioners	Possible comparator companies
Royal College of Nursing	A Menarini Farmaceutica Internazionale
Royal College of Pathologists	SRL (bilastine)
Royal College of Physicians	Advanz Pharma (methotrexate)
Royal Pharmaceutical Society	Amarox (montelukast)
Royal Society of Medicine	Astellas Pharma (tacrolimus)
UK Clinical Pharmacy Association	Aurobindo Pharma – Milpharm
,	(bilastine, cetirizine hydrochloride,
<u>Others</u>	montelukast)
Department of Health and Social Care	The Boots Company (cetirizine
NHS England	hydrochloride, fexofenadine
_	hydrochloride, loratadine, ranitidine)
	Bristol laboratories (cetirizine
	hydrochloride)
	Brown and Burk (acrivastine, loratadine,
	levocetirizine dihydrochloride)

Final stakeholder list for the evaluation of remibrutinib for treating chronic spontaneous urticaria inadequately controlled by H1-antihistamines ID6356



Provisional Consultees	Provisional Commentators (no right to submit or appeal)
	Celltrion Healthcare UK (omalizumab) Cipla EU (cetirizine hydrochloride, fexofenadine hydrochloride, methotrexate) Chiesi (tacrolimus) Dexcel Pharma (ciclosporin) Dr Reddy's Laboratories (cetirizine hydrochloride, fexofenadine hydrochloride, montelukast) Flamingo Pharma UK (cetirizine hydrochloride, loratadine) Haleon UK trading (cetirizine hydrochloride, fexofenadine hydrochloride) Hospira (methotrexate) Glenmark Pharmaceuticals (desloratadine, levocetirizine dihydrochloride, montelukast) Krka (desloratadine, montelukast) Krka (desloratadine, montelukast) Leo Laboratories (tacrolimus) McNeil products (acrivastine, cetirizine hydrochloride) Medac Pharma (methotrexate) Medley Pharma (cimetidine) Morningside Healthcare (methotrexate) Mylan (ciclosporin, desloratadine, nizatidine) Novartis Pharmaceuticals (ciclosporin, omalizumab) Novumgen (levocetirizine dihydrochloride) Opella Healthcare (fexofenadine hydrochloride) Opella Healthcare (fexofenadine, montelukast) Orion Pharma (methotrexate) Pinewood Healthcare (cetirizine hydrochloride, loratadine) Ranbaxy (UK) a Sun Pharmaceutical Company (ciclosporin, loratadine,
	 montelukast) Reckitt Benckiser Healthcare (ranitidine) Rivopharm (desloratadine, montelukast)



Provisional Consultees	Provisional Commentators (no right to submit or appeal)
	 Roche Products (mycophenolate mofetil) Rosemont Pharmaceuticals (cimetidine, methotrexate, mycophenolate mofetil) Sandoz (methotrexate, montelukast, tacrolimus) Santen (ciclosporin) Sigma Pharmaceuticals PLC (cetirizine hydrochloride) Teva Pharma B.V. (mycophenolate mofetil) Tillomed Laboratories (mycophenolate mofetil) UCB pharma (cetirizine hydrochloride, levocetirizine dihydrochloride) Wockhardt (cetirizine hydrochloride) Zentiva (fexofenadine hydrochloride) Zentiva (fexofenadine hydrochloride) Relevant research groups British Skin Foundation Cochrane Skin Group Genomics England MRC Clinical Trials Unit National Institute for Health Research Associated Public Health groups Public Health Wales
	UK Health Security Agency


NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

Consultees

Final stakeholder list for the evaluation of remibrutinib for treating chronic spontaneous urticaria inadequately controlled by H1-antihistamines ID6356



Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.